RA Capital Management - Q3 2022 holdings

$4.69 Billion is the total value of RA Capital Management's 81 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 37.5% .

 Value Shares↓ Weighting
ASND  ASCENDIS PHARMA A/Ssponsored adr$781,462,000
+11.1%
7,567,9000.0%16.67%
-11.1%
BIIB BuyBIOGEN INC$250,325,000
+68.8%
937,549
+29.0%
5.34%
+35.1%
 CYTEK BIOSCIENCES INC$196,969,000
+37.2%
13,381,0540.0%4.20%
+9.8%
FMTX  FORMA THERAPEUTICS HLDGS INC$179,782,000
+189.6%
9,011,6510.0%3.84%
+131.7%
DAWN  DAY ONE BIOPHARMACEUTICALS I$141,024,000
+11.9%
7,040,6220.0%3.01%
-10.5%
AVTE  AEROVATE THERAPEUTICS INC$137,017,000
+6.1%
8,263,9820.0%2.92%
-15.1%
RYTM BuyRHYTHM PHARMACEUTICALS INC$134,041,000
+563.1%
5,471,067
+12.3%
2.86%
+430.6%
TVTX  TRAVERE THERAPEUTICS INC$121,301,000
+1.7%
4,922,9410.0%2.59%
-18.6%
BLU BuyBELLUS HEALTH INC NEW$120,232,000
+27.2%
11,385,574
+11.3%
2.56%
+1.8%
JANX  JANUX THERAPEUTICS INC$117,401,000
+10.9%
8,670,6440.0%2.50%
-11.3%
PCVX  VAXCYTE INC$109,949,000
+10.3%
4,581,2030.0%2.35%
-11.7%
 DICE THERAPEUTICS INC$105,637,000
+30.7%
5,208,9110.0%2.25%
+4.6%
IMGN  IMMUNOGEN INC$103,924,000
+6.2%
21,741,4580.0%2.22%
-15.0%
NKTX  NKARTA INC$102,716,000
+6.8%
7,805,1290.0%2.19%
-14.5%
ABOS  ACUMEN PHARMACEUTICALS INC$98,001,000
+113.4%
9,770,7730.0%2.09%
+70.8%
LEGN NewLEGEND BIOTECH CORPsponsored ads$95,415,0002,338,610
+100.0%
2.04%
ITOS  ITEOS THERAPEUTICS INC$84,149,000
-7.5%
4,417,2590.0%1.80%
-26.0%
RLMD  RELMADA THERAPEUTICS INC$74,040,000
+94.9%
2,000,0000.0%1.58%
+56.0%
 PEPGEN INC$73,838,000
-8.6%
8,131,9520.0%1.58%
-26.8%
GERN  GERON CORP$70,496,000
+51.0%
30,126,2990.0%1.50%
+20.8%
ACRS  ACLARIS THERAPEUTICS INC$69,231,000
+12.7%
4,398,4530.0%1.48%
-9.8%
NewTHIRD HARMONIC BIO INC$65,934,0003,475,687
+100.0%
1.41%
BuyAN2 THERAPEUTICS INC$65,584,000
+125.8%
3,773,517
+0.7%
1.40%
+80.5%
 TYRA BIOSCIENCES INC$63,609,000
+22.9%
7,236,4540.0%1.36%
-1.7%
WVE  WAVE LIFE SCIENCES LTD$62,099,000
+11.1%
17,202,0090.0%1.32%
-11.1%
VRNA BuyVERONA PHARMA PLCsponsored ads$61,831,000
+189.3%
6,050,000
+18.6%
1.32%
+131.4%
COGT NewCOGENT COMMUNICATIONS HLDGS$59,881,0004,013,453
+100.0%
1.28%
NSTG BuyNANOSTRING TECHNOLOGIES$58,774,000
+29.1%
4,602,478
+28.4%
1.25%
+3.3%
CLDX  CELLDEX THERAPEUTICS INC NEW$58,328,000
+4.3%
2,075,0000.0%1.24%
-16.6%
GHRS  GH RESEARCH PLCordinary shares$56,919,000
+16.4%
4,898,3730.0%1.21%
-6.8%
FULC NewFULCRUM THERAPEUTICS INC$56,630,0007,000,000
+100.0%
1.21%
KNTE  KINNATE BIOPHARMA INC$50,956,000
-5.2%
4,264,1440.0%1.09%
-24.2%
ENTA  ENANTA PHARMACEUTICALS INC$46,513,000
+9.7%
896,7240.0%0.99%
-12.2%
DSGN BuyDESIGN THERAPEUTICS INC$46,368,000
+51.5%
2,773,231
+26.8%
0.99%
+21.2%
ETNB  89BIO INC$45,062,000
+79.8%
7,782,6690.0%0.96%
+43.9%
VOR  VOR BIOPHARMA INC$44,261,000
-19.9%
11,120,9730.0%0.94%
-36.0%
 ELIEM THERAPEUTICS INC$42,477,000
+7.0%
13,150,8490.0%0.91%
-14.4%
TIL  INSTIL BIO INC$37,127,000
+4.8%
7,670,7930.0%0.79%
-16.2%
 RXSIGHT INC$36,633,000
-14.8%
3,052,7960.0%0.78%
-31.8%
STSA  SATSUMA PHARMACEUTICALS INC$35,486,000
+44.9%
5,914,2520.0%0.76%
+15.9%
RNA  AVIDITY BIOSCIENCES INC$35,393,000
+12.4%
2,167,3910.0%0.76%
-10.1%
VERA  VERA THERAPEUTICS INCcl a$33,645,000
+56.6%
1,578,8200.0%0.72%
+25.3%
RCKT  ROCKET PHARMACEUTICALS INC$33,630,000
+16.0%
2,107,1490.0%0.72%
-7.2%
AKRO NewAKERO THERAPEUTICS INC$32,653,000958,980
+100.0%
0.70%
ALPN NewALPINE IMMUNE SCIENCES INC$31,368,0004,356,632
+100.0%
0.67%
 HILLEVAX INC$30,079,000
+56.4%
1,760,0190.0%0.64%
+25.1%
ACET NewADICET BIO INC$29,284,0002,059,372
+100.0%
0.62%
EYPT  EYEPOINT PHARMACEUTICALS INC$26,660,000
+0.5%
3,370,5060.0%0.57%
-19.5%
MIST  MILESTONE PHARMACEUTICALS IN$20,645,000
+49.4%
2,246,5030.0%0.44%
+19.6%
PMVP  PMV PHARMACEUTICALS INC$20,352,000
-16.5%
1,710,2650.0%0.43%
-33.2%
HOWL  WEREWOLF THERAPEUTICS INC$19,356,000
+10.3%
4,291,8810.0%0.41%
-11.8%
 ICOSAVAX INC$18,845,000
-44.9%
5,963,5650.0%0.40%
-55.9%
VRDN NewVIRIDIAN THERAPEUTICS INCsponsored ads$18,049,000880,000
+100.0%
0.38%
RLAY BuyRELAY THERAPEUTICS INC$16,053,000
+74.5%
717,618
+30.7%
0.34%
+39.6%
 DA32 LIFE SCNCE$14,595,000
+0.4%
1,500,0000.0%0.31%
-19.8%
BLSA  BCLS ACQUISITION CORP$12,525,000
+1.2%
1,250,0000.0%0.27%
-19.1%
 PARDES BIOSCIENCES INC$11,424,000
-39.7%
6,175,0380.0%0.24%
-51.7%
ACHL  ACHILLES THERAPEUTICS PLCsponsored ads$11,333,000
-10.3%
5,014,6870.0%0.24%
-28.2%
FLACU  FRAZIER LIFESCIENCES ACQU CO$9,980,000
+1.1%
1,000,0000.0%0.21%
-19.0%
 ARYA SCIENCES ACQUISITN CORP$9,800,000
+0.8%
1,000,0000.0%0.21%
-19.3%
CNTB  CONNECT BIOPHARMA HLDGS LTDads$9,018,000
+48.3%
6,991,0030.0%0.19%
+18.5%
BuyAADI BIOSCIENCE INC$8,340,000
+76.7%
590,218
+54.1%
0.18%
+41.3%
FVAM  5 01 ACQUISITION CORP$7,500,000
+1.0%
750,0000.0%0.16%
-19.2%
CNCE SellCONCERT PHARMACEUTICALS INC$7,292,000
-47.6%
1,088,296
-67.1%
0.16%
-58.0%
DBVT NewDBV TECHNOLOGIES S Asponsored adr$6,593,0003,724,740
+100.0%
0.14%
HSAQ SellHEALTH SCIENCES ACQ CORP 2$6,042,000
-2.9%
610,283
-2.4%
0.13%
-22.3%
SLDB  SOLID BIOSCIENCES INC$5,771,000
-24.2%
12,367,8730.0%0.12%
-39.4%
ATHA  ATHIRA PHARMA INC$5,578,000
-2.6%
1,878,0000.0%0.12%
-22.2%
MGTA NewMAGENTA THERAPEUTICS INC$5,059,0003,588,081
+100.0%
0.11%
 IO BIOTECH INC$5,035,000
-42.0%
1,857,7550.0%0.11%
-53.7%
SellTENAYA THERAPEUTICS INC$4,646,000
-76.8%
1,602,009
-54.9%
0.10%
-81.4%
SYBX SellSYNLOGIC INC$4,387,000
-34.5%
4,618,415
-20.7%
0.09%
-47.5%
BDTX  BLACK DIAMOND THERAPEUTICS I$4,377,000
-31.3%
2,589,9040.0%0.09%
-45.3%
CVRX  CVRX INC$2,566,000
+55.2%
275,0000.0%0.06%
+25.0%
ENTX SellENTERA BIO LTD$2,166,000
-30.8%
2,082,372
-11.5%
0.05%
-44.6%
FUSN NewFUSION PHARMACEUTICALS INC$1,987,000659,992
+100.0%
0.04%
SellPYXIS ONCOLOGY INC$1,506,000
-33.6%
764,653
-19.8%
0.03%
-46.7%
SNSE SellSENSEI BIOTHERAPEUTICS$1,059,000
-35.5%
683,529
-5.5%
0.02%
-47.7%
BOLT BuyBOLT BIOTHERAPEUTICS INC$789,000
-14.1%
533,432
+18.5%
0.02%
-29.2%
APTX NewAPTINYX INC$720,0001,954,698
+100.0%
0.02%
AGLE NewAEGLEA BIOTHERAPEUTICS INC$5,00010,439
+100.0%
0.00%
CLBS ExitCALADRIUS BIOSCIENCES$0-752,500
-100.0%
-0.01%
AVRO ExitAVROBIO INC$0-559,600
-100.0%
-0.01%
OLMA ExitOLEMA PHARMACEUTICALS INC$0-233,793
-100.0%
-0.02%
ORTX ExitORCHARD THERAPEUTICS PLCads$0-3,040,885
-100.0%
-0.05%
LRMR ExitLARIMAR THERAPEUTICS INC$0-1,031,482
-100.0%
-0.05%
ADVM ExitADVERUM BIOTECHNOLOGIES INC$0-1,726,019
-100.0%
-0.06%
ExitASTRIA THERAPEUTICS INC$0-760,857
-100.0%
-0.06%
BCAB ExitBIOATLA INC$0-1,031,805
-100.0%
-0.08%
TERN ExitTERNS PHARMACEUTICALS INC$0-1,261,435
-100.0%
-0.08%
FLDM ExitSTANDARD BIOTOOLS INC$0-1,987,589
-100.0%
-0.08%
ExitXILIO THERAPEUTICS INC$0-1,649,711
-100.0%
-0.13%
BMEA ExitBIOMEA FUSION INC$0-500,000
-100.0%
-0.16%
IPSC ExitCENTURY THERAPEUTICS INC$0-756,821
-100.0%
-0.17%
ExitLIANBIOsponsored ads$0-4,622,574
-100.0%
-0.27%
OTIC ExitOTONOMY INC$0-5,600,000
-100.0%
-0.31%
GH ExitGUARDANT HEALTH INC$0-476,380
-100.0%
-0.51%
DYN ExitDYNE THERAPEUTICS INC$0-2,805,045
-100.0%
-0.51%
NTRA ExitNATERA INC$0-1,310,289
-100.0%
-1.24%
PNT ExitPOINT BIOPHARMA GLOBAL INC$0-9,003,018
-100.0%
-1.64%
VERU ExitVERU INC$0-7,900,000
-100.0%
-2.38%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-11-14
Signatures

The EDGAR filing(s) were signed by:

About RA Capital Management

RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.

The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.

RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.

Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.

Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ASCENDIS PHARMA A/S - ADR35Q3 202325.5%
WAVE LIFE SCIENCES PTE LTD32Q3 202326.3%
TG THERAPEUTICS INC30Q4 20216.3%
ZOGENIX INC26Q4 20219.5%
BIOCRYST PHARMACEUTICALS23Q1 20199.2%
DICERNA PHARMACEUTICALS INC23Q3 20195.8%
RHYTHM PHARMACEUTICALS INC22Q3 20234.4%
ACHILLION PHARMACEUTICALS INC19Q4 201717.2%
KALA PHARMACEUTICALS INC19Q1 20224.4%
SOLID BIOSCIENCES INC19Q3 20226.8%

View RA Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
RA Capital Management Q3 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
ARS Pharmaceuticals, Inc.September 25, 20239,459,6789.9%
CymaBay Therapeutics, Inc.September 22, 20236,940,0006.2%
BELLUS Health Inc.Sold outAugust 14, 202300.0%
Kinnate Biopharma Inc.Sold outAugust 14, 202300.0%
Vor Biopharma Inc.August 11, 202322,780,34333.7%
DICE Therapeutics, Inc.Sold outAugust 09, 202300.0%
Acumen Pharmaceuticals, Inc.July 25, 202314,981,61825.9%
Talaris Therapeutics, Inc.July 06, 20232,333,1755.5%
Aerovate Therapeutics, Inc.June 27, 20238,293,14830.0%
Satsuma Pharmaceuticals, Inc.Sold outJune 12, 202300.0%

View RA Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D/A2024-02-27
SC 13G2024-02-26
SC 13G2024-02-22
SC 13D/A2024-02-21
42024-02-20
13F-HR2024-02-14
42024-02-14
SC 13D/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View RA Capital Management's complete filings history.

Compare quarters

Export RA Capital Management's holdings